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Abstract
Mutations in alpha1-antitrypsin (AAT) can cause the protein to polymerise and be retained in the endoplasmic reticulum (ER) of
hepatocytes. The ensuing systemic AAT deficiency leads to pulmonary emphysema, while intracellular polymers are toxic and
cause chronic liver disease. The severity of this process varies considerably between individuals, suggesting the involvement of
mechanistic co-factors and potential for therapeutically beneficial interventions. We show in Hepa1.6 cells that the mildly
polymerogenic I (Arg39Cys) AAT mutant forms aberrant inter- and intra-molecular disulphide bonds involving the acquired
Cys39 and the only cysteine residue in the wild-type (M) sequence (Cys232). Substitution of Cys39 to serine partially restores
secretion, showing that disulphide bonding contributes to the intracellular retention of I AAT. Covalent homodimers mediated
by inter-Cys232 bonding alone are also observed in cells expressing the common Z and other polymerising AAT variants where
conformational behaviour is abnormal, but not in those expressing M AAT. Prevention of such disulphide linkage through the
introduction of the Cys232Ser mutation or by treatment of cells with reducing agents increases Z AAT secretion. Our results
reveal that disulphide interactions enhance intracellular accumulation of AATmutants and implicate the oxidative ER state as a
pathogenic co-factor. Redox modulation, e.g. by anti-oxidant strategies, may therefore be beneficial in AAT deficiency-
associated liver disease.
Introduction
Alpha1-antitrypsin (AAT) is an acute phase glycoprotein pro-
duced and secreted by liver cells. It inhibits neutrophil elastase,
protecting lung tissue from excessive damage during inflamma-
tory responses. Mutations in the SERPINA1 gene (OMIM 107400)
encoding AAT cause the hereditary autosomal disorder alpha-1
antitrypsin deficiency (AATD, OMIM 613490) (1). Pathological
AAT variants are either ‘null’ (no detectable levels of AAT in the
plasma, e.g. due to premature stop codons) or ‘deficient’, where
missensemutations or small deletions result in synthesis of con-
formationally altered AAT and retention within the endoplasmic
reticulum (ER). These mutants engage with a number of ER
quality-control mechanisms.
The most frequent genotype associated with severe AATD is
homozygosity for the Z (Glu342Lys) allele. This is associated
with plasma AAT levels that are 10–15% of normal and early-
onset emphysema in adults due to protease:antiprotease
imbalance in the lung. A subset of ZZ patients also develop
liver diseases, e.g. neonatal hepatitis, liver cirrhosis and hepato-
cellular carcinoma. Liver disease is associated histopathological-
ly with accumulation of Z AAT protein inclusions in the ER of
hepatocytes (2). The majority of synthesized Z AAT is degraded
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by ER-associated degradation (ERAD) (3,4). However, a proportion
escapes degradation and self-associates to form ordered poly-
meric structures that accumulate in dilated cisternae of the ER
as inclusion bodies. Liver manifestations vary significantly
among ZZ patients, implicating additional genetic and environ-
mental factors in the onset of liver pathologies associated with
AATD. Hypomorphic variants of ERAD or autophagy pathway
components have been proposed as co-factors predisposing to
accumulation of Z AAT polymers to cause hepatotoxicity (5).
Besides Z, many other AAT mutants have been identified in
AATD patients. The S variant (Glu264Val) is relatively frequent
in South-West European countries and is associated with a
milder secretory deficiency. Rarer variants are increasingly iden-
tified in AATD patients, often compound heterozygotes who also
carry the Z allele (1,6). A subset of rare variants form polymeric
structures and intracellular inclusions similar to Z AAT and so
contribute to both liver disease risk and severe secretory defect.
Examples include Mmalton (ΔPhe52), Siiyama (Ser53Pro), King’s
(His334Pro) and Pbrescia (Gly225Arg) (1).
A further variant in this class is the I variant (Arg39Cys), that
is now well-recognized in Europe (7). It was first reported in a IZ
heterozygous patient with emphysema (8). A child with IZ geno-
typewas then reportedwith evidence of liver disease. In vitro cell-
free assays indicated that purified I AATwas as polymerogenic as
the S variant. This similarity may be rationalized by reference to
the X-ray crystallographic structure of AAT; Arg39, the site of the I
mutation, lies within part of the A helix of AAT that interacts
directly with Glu264, the site of the S mutation (9).
The amino acid substitution of the I variant causes AAT to
acquire a second cysteine residue in addition to Cys232 that is pre-
sent in thewild-type (M) AAT. Cysteines normally formdisulphide
bonds in the ER environment (10). This process is catalyzed by
members of the protein disulphide isomerase (PDI) family in
appropriate redox conditions (11,12). Non-native intra- or inter-
molecular disulphide bonds may form transiently during folding
but can be isomerized by PDI family members to more stable
native disulphides. Mutations affecting cysteine residues (e.g.
causing their gain or loss) may result in abnormal intra- or inter-
chain disulphides with ER-resident or cargo proteins that prevent
export of the unfolded/misfolded proteins. We investigated the
role of such events in the transport andaggregation of the I variant
and other deficiency mutants in Hepa 1.6 cells. Our results show
that aberrant intra- and inter-molecular disulphide bonding be-
tween disease-variant AAT molecules contributes to ER retention
and impedes transport to distal compartments of the secretory
pathway. The effects are greatest for the I variant, but this process
also affects the more common Z variant.
Results
AAT variants form intra-cellular disulphide-linked
complexes
We set out to investigatewhether the additional cysteine found in
I AAT besides Cys232 in thewild-type (M) sequence couldmediate
aberrant disulphide bonds and contribute to secretion defects.We
used a liver-derived cellularmodel previously used to characterize
other rare deficiency AAT variants (13,14).We compared the I mu-
tant with M AAT, the common Z (Glu342Lys) mutant and two fur-
thermild deficiency variants containing an extra cysteine residue:
the previously reported F variant (Arg223Cys) (15) anda novel, nat-
urally occurring mutant we have named Brixia (Phe35Cys). The
Brixia allele was identified in a 40-year-old male heterozygote re-
ferred at Spedali Civili (Brescia, Italy) because of mildly reduced
plasma AAT levels (89 mg/dl; 90–220 mg/dl normal range). The
newallele shows a T>G transversion in exon2 (c.176T>G) resulting
in Phe35Cys substitution.
We first analysed the five AAT variants by metabolic labelling
of Hepa1.6 transient transfectants. Importantly, post-lysis,
artefactual disulphide bonding interactions were prevented by
N-ethylmaleimide (NEM) treatment. All fractions were immuno-
precipitated by a polyclonal anti-AAT antibody and analysed by
sodium dodecyl sulphate-polyAcrilamyde gel electrophoresis
(SDS-PAGE) under non-reducing conditions in order to detect the
presence of disulphide-linked complexes (Fig. 1A, upper panels).
Wild-typeMAATshowed theexpectedpattern: detectedmainly
as an immature high-mannose monomer in the NP40-soluble cel-
lular fraction and efficiently secreted in the cell media as a mature
glycosylated form. All mutants were secreted as fully glycosylated
monomers but at lower levels compared with M, with I being the
most deficient among the rare variants (by densitometric analysis
Z, F, Brixia and Iwere, respectively, 8, 49, 55 and 31%of theM levels).
The I mutant forms multiple high molecular weight complexes
both in soluble and insoluble cellular fractions. These dissociate
upon reduction (Fig. 1A, lower panels), confirming that they are sta-
bilized by disulphide bonds. The faster migrating complex has an
apparent molecular weight of 100 kDa, followed by higher molecu-
lar weight complexes. The Brixia mutation occurs close to that of
the I variant on the A helix and shows similar disulphide-linked
complexes with the 100 kDa form prevalent. A 140 kDa covalent
complex was also observed in F, Z and other disease associated
AAT mutants (Supplementary Material, Fig. S1), but not in M AAT,
suggesting formation of dimers by Cys232 in variants with abnor-
mal conformation and ER retention. Similar results were obtained
by immunoblot analysis with anti-AAT antibodies (not shown).
To further investigate the nature of the disulphide-linked com-
plexes formed by AATmutants, we performed diagonal gels, con-
sisting of non-reducing SDS-PAGE in the first dimension followed
by a reducing SDS-PAGE in the second dimension (Fig. 1B). As ex-
pected, thewild-typeAATM (top left panel) shows themonomeric
form and runs in the second dimension as a train of spots along
the diagonal, indicating that neither intra- nor inter-chain disul-
phide bonds are formed as the protein undergoes glycan process-
ing. The disulphide complex of the Z mutant with an apparent
molecular weight of 140 kDa migrates in the reducing dimension
as a high-mannose immaturemonomer, suggesting that the com-
plex is a covalently linked ZAAThomodimer. I and Brixiamutants
show similar behaviour, with all major disulphide complexes
dissociating into monomeric AAT. No other proteins were found
associated with AAT in this analysis, under the experimental con-
ditions adopted, even at longer exposure times. This is consistent
with the retained highermass species being composed entirely of
AAT subunitswith a range of disulphide linkage patterns.We can-
not formally exclude interactions of AAT with additional long-
lived proteins or methionine/cysteine-poor proteins, due to the
nature of the pulse-chase radiolabelling approach. However, our
findings suggest that if they occur, heterotypic interactions are a
minor contributor to the observed profile of disulphide-adducted
AAT species. Importantly, a proportion of I and Brixia AAT runs
faster than fully extended monomers in the first dimension
(Fig. 1A and B, asterisks) and thenmigrates as a full-lengthmono-
mer in the reducing second dimension (arrows), consistent with
the presence of an intra-chain disulphide bond. An intra-chain
form was not evident for the F mutant. In this case, the acquired
Cys223 lieswithin the same β-strand as Cys232 in the native struc-
ture. Formation of an intra-chain bond would likely necessitate
major disruption of the protein backbone and stabilising
interactions relative to the native structure with kinetically and
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energetically unfavourable consequences. We therefore favour
this over the alternative interpretation that a disulphide bridge
can form but does not result in a significant change in migration
on SDS-PAGE. The presence of a second cysteine in the F variant
is also associated with less extensive formation of higher molecu-
lar weight disulphide species than the other AAT mutants con-
taining two cysteines.
Disulphide-linked complexes are distinct from classical
polymers
Inclusions formed in the hepatocytes of Z homozygotes are com-
posed of polymers that are well-recognized by the conformation-
specific monoclonal antibody (mAb) 2C1 (16). To date all AAT
polymers that have been assessed in tissue or cell models have
also been recognized by the 2C1 mAb. To investigate whether
disulphide-linked complexes are associated with 2C1-positive
polymeric structures, we performed immunoprecipitation of
NP40-soluble fractions obtained as in Figure 1 with the 2C1 mAb
(Fig. 2, left). The residual solution was then subjected to immuno-
precipitation for total AAT using a polyclonal antibody (Fig. 2,
right). About 25% of total Z variant migrating in SDS-PAGE as
monomer is immunoprecipitated by 2C1 mAb reflecting the frac-
tion of intracellular Z in polymeric forms. Instead the disulphide-
linked dimers and the other disulphide-linked species were less
efficiently immunoprecipitated by 2C1 (<10%). These observations
suggest that the disulphide-linked species are not incorporated
into classical polymers recognized by 2C1 mAb, but may be incor-
porated in distinct aggregation states.
Cysteine-mediated interactions contribute to ER retention
of AAT mutants
To dissect the individual roles of the two cysteines in determin-
ing the intracellular fate of I AAT, we generated two I AAT
Figure 2. 2C1 fails to immunoprecipitate disulphide-linked complexes. NP-40
soluble cell lysates of Hepa1.6 cells expressing M, Z, F, Brixia (Bx) or I, metabolically
labelled for 4 h with 35S Met/Cys as in Figure 1A, were immunoprecipitated with
the 2C1 mAb (IP1, left side), and the leftover further immunoprecipitated by an
anti-total AAT polyclonal antibody (IP2, right side). Immunoprecipitated
samples were analysed by non-reducing 8% SDS-PAGE and autoradiography.
The results shown are representative of two independent experiments.
Figure 1. AAT mutants form intracellular disulphide-linked complexes. Hepa1.6
cells were transfected with vectors encoding the AAT variants M, Z, F, Brixia
(Bx) or I. Twenty-four hours after transfection the cells were metabolically
labelled for 4 h with 35S Met/Cys. Cell media were collected, the cells lysed in 1%
NP40 buffer and theNP40-insoluble fractions solubilized in 1% SDS buffer. (A) AAT
was immunoprecipitated from the culture media and the intracellular fractions
and analysed by 8% SDS-PAGE under non-reducing conditions (upper panels) or
reducing conditions (lower panels), followed by autoradiography. White
arrowhead: immature AAT. Black arrowhead: mature AAT. (B) NP-40 soluble cell
lysates obtained as in (A) were analysed by diagonal gels. The samples were
first resolved by non-reducing 8% SDS-PAGE; for the second dimension,
individual lanes were cut, reduced with Laemmli buffer containing 100 mM DTT
and further subjected to 8% SDS-PAGE analysis and autoradiography. First
dimension lanes are shown at the top of each panel. Asterisks indicate the I
and Brixia AAT conformers with an intrachain disulphide bond, which run in
the second dimension as reduced monomeric AAT (arrows). The results shown
are representative of two independent experiments.
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variants (IC39S and IC232S) with Cys39 or Cys232, respectively, sub-
stituted with serines. Serine residues are chemically similar to
cysteines but cannot form disulphide bonds. We expressed
these artificial mutants in Hepa1.6 cells and compared their
behaviour with that of M, Z and I AAT. Cells were metabolically
labelled and analysed by non-reducing SDS-PAGE (Fig. 3). IC39S
AAT formed a Cys232-Cys232 disulphide-bonded dimer that mi-
grated close to the molecular weight marker of 140 kDa. A dimer
with identical behaviour was observed in cells expressing Z AAT.
On the other hand, IC232S expression formed a Cys39-Cys39 disul-
phide-linked dimer that migrated more rapidly (apparent mass
100 kDa) likely due to a compact structure and was also found
in the cell media (Fig. 3B). A further dimer species was apparent
in cells expressing the I variant that migrated intermediate be-
tween these points and likely involves both cysteine residues.
Formation of higher order complexeswas indicated by slowermi-
grating species.
The disulphide-linked pattern observed for Brixia was more
consistent with that seen in IC232S than in I variant containing
Cys232. Most likely, therefore, Brixia dimer formation was
mediated byCys35 rather thanCys232. The variation in disulphide
bonding between the I and Brixia variants, which both have two
cysteines in near-identical positions, indicates differences in
dynamic folding and/or conformational behaviour.
Levels of AAT secreted by cells expressing different AAT var-
iantswere thenanalysedbyquantitative enzyme-linked immuno-
sorbent assay (ELISA) (Fig. 3C). F and Brixia mutant secretion was
mildly deficient relative to theMAAT control (75 and 80%, respect-
ively) while Z and I showed severe deficiency (respectively, 13 and
20%). Notably, secretion of the IC39S and IC232Smutants was signifi-
cantly higher than that of I, indicating that the formation of het-
erogeneous disulphide complexes in the ER contributes to the
secretory defect of the I variant. Interestingly, intracellular co-ag-
gregation and disulphide bonding of I and Z AAT were demon-
strated when they were co-expressed to model hepatocyte
behaviour in IZ compound heterozygotes (Supplementary Mater-
ial, Fig. S2). Such individuals are more likely to be encountered in
clinical practice than I homozygotes. The observation that co-ex-
pression of a second, milder deficiency variant can result in com-
plex formationwith the Z variant in the ER environment validates
a previous proposal based upon biophysical studies in cell-free
conditions (9).
Effects of disulphide bonding on maturation
and secretion of I AAT
To further investigate the kinetics of formation of the disulphide-
linked complexes and their effects on secretion, we performed
pulse-chase experiments (Fig. 4). The electrophoretic patterns of
the I mutant revealed that intra-chain disulphides and Cys39-
mediated homodimers form very soon after synthesis. Inter-
chain Cys232-Cys232 bonds appear to form more slowly, and the
three dimer isoforms are similarly represented from the 30 min
time point. Intra-chain bonding is associated with reduced per-
sistenceofmonomericAATsince the populationof this species at-
tenuates steadily. This likely reports abnormal conformational
behaviour, favouring degradation and/or polymerization. Higher
order forms become prevalent at later time points. As expected,
IC39S and IC232S AAT form only homodimers and show increased
secretion with faster intracellular maturation to the 56 kDa glyco-
sylated form that acquires Golgi processing. Some IC232S homodi-
mers were secreted, whilst only IC39S monomers accumulated
extracellularly. The distribution of AAT in the intracellular frac-
tions and in the cell media at different time points was quantified
by densitometry on reducing SDS-PAGE gels and are shown in
Supplementary Material, Figure S3. The effects of aberrant disul-
phide bonding upon I AAT secretion were determined by densito-
metric analysis of data from two independent pulse-chase
experiments (Fig. 4A, lower panel). At 240 min of chase, when
about 60% of the wild-type M was found in the culture medium,
10, 26 and 13%, respectively, of I, IC39S and IC232S AATwere secreted.
The significant increase in secretion associated with Cys39Ser
substitution further confirms that Cys39-mediated disulphide
bonding promotes I AAT retention.
Figure 3. Effects of Cys39 and Cys232 substitution. Hepa1.6 cells were transfected
with vectors encoding the AAT variants M, Z, F, Brixia (Bx) or I, and the artificial
mutants IC39S and IC232S. (A and B) Transfected cells were metabolically
labelled for 4 h and processed as in Figure 1. Immunoprecipitated AAT from the
NP-40-soluble cellular fractions (panel A) and cell media (panel B) were
analysed by non-reducing 8% SDS-PAGE and autoradiography. (C) Transfected
Hepa1.6 cells were incubated for 6 h in serum-free culture medium. Secreted
AAT levels in the media were quantified by sandwich ELISA using a standard
curve of purified AAT and expressed as percentages of the wild-type M levels.
Results are presented as means and SD of three independent transfection
experiments. Statistical significance was determined by one-way ANOVA
followed by the Bonferroni’s post-hoc test using GraphPad Prism version 5
(Graphpad software Inc., San Diego, CA, USA): *P < 0.05; **P < 0.01.
Human Molecular Genetics, 2016, Vol. 25, No. 4 | 645
 at U
niversitÃ









Preventing aberrant disulphide bond formation increases
secretion of Z AAT
To specifically address the role of aberrant Cys232 thiol interac-
tions in the retention of Z AAT, we performed four independent
pulse-chase experiments, comparing Z with a Z mutant in
whichCys232was substituted for a serine (ZC232S). Cys232Ser sub-
stitution significantly increased Golgi maturation and secretion
of Z AAT (Fig. 5A), indicating that Cys232-mediated disulphide
bonding plays a role in the intracellular retention of Z AAT.
Cell treatment with reducing agents has been used previously
to shift the ER to amore reducing state and impair the formationof
disulphides on cargo proteins (17,18). Therefore, we next assessed
whether such treatment could thereby increase the secretion of
Z AAT from Hepa1.6 cells similarly to the effect of the Cys232Ser
mutation. A significant increase in secretion of Z AAT was ob-
served upon treatment with 0.5 mM dithiothreitol (DTT) (Fig. 5B).
This was of similar magnitude to the increase in secretion result-
ing from the introduction of the Cys232Ser mutation. To assess
how far this increase could be attributed to the rescue of Cys232-
mediated aggregation, as opposed to the knownpleiotropic effects
of DTTupon cells,we similarly treated cells expressing ZC232S AAT.
Treatment of these control cells did not increase AAT secretion
whatsoever, indicating that this effect of DTT was indeed due to
inhibition of Cys232-mediated Z AAT aggregation within cells.
Only fully glycosylated AAT was detected in the cell media upon
treatment with DTT and we did not observe major effects on the
intracellular degradation of the proteins. Consistent results were
obtained by measuring secreted AAT by ELISA in the culture
media of Hepa1.6 cells expressing Z, treated with either 2ME or
DTT. Notably, the change in I AAT secretion was smaller and did
not achieve significance, consistentwith themore extensive disul-
phide bonding patterns observed in this mutant.
Discussion
The oxidizing environment of the ER lumen favours disulphide
bonding during the biosynthesis and maturation of secreted pro-
teins. The process is assisted by numerous disulphide isomerases
and oxidases, working in a tightly controlled redox environment
(11). The interaction between free exposed cysteines and disul-
phide isomerases also serve to prevent unfolded and unas-
sembled proteins from exiting the ER, and so are fundamental in
protein quality-control within the early secretory compartment
(10). Such thiol-dependent ER retention was originally described
for unassembled IgM subunits (19,20) and was then shown for
other substrates (21,22). Moreover proteins exposing free cysteine
residues may be retrieved from ER-Golgi intermediate compart-
ment to the ER by pH-dependent interactions with ERp44 (23,24).
The stringency of thiol-mediated retention can be modulated by
the local pKa of the thiol group, as demonstrated by the lower re-
activity of the IgA C-terminal cysteine due to the presence of an
adjacent negatively charged amino acid (25).
Human AAT appears to represent an exception to this general
model of thiol-dependent quality-control: it contains a single
cysteine residue (Cys232) at a solvent-exposed site yet is an effi-
ciently secreted protein. The reason for this discrepancy is un-
clear but does not obviously relate to masking of Cys232 that
might render it poorly reactive and/or not accessible in the native
structure. Biochemical studies have demonstrated that Cys232 of
recombinant AAT has a pKa of 6.86 and can be efficiently oxidized
in vitro (26). Moreover, high resolution crystal structures of AAT
indicate that the thiol group of Cys232 is highly exposed to the
solvent and electron density maps are consistent with an oxi-
dized state (PDB IDs: 2QUG and 3NE4 (27,28). Whether Cys232 in-
teracts with protein isomerases in the secretory pathway,
however, remains to be elucidated.
Here we report that the Z mutant as well as other transport-
incompetent AAT variants form disulphide-linked homodimers
in the ER. This suggests that Cys232 participates in disulphide
bonding events that report abnormal conformational behaviour
of AAT and stabilize aberrant conformations in pathogenic AAT
Figure 4. Effects of disulphide bonding on maturation and secretion of I AAT.
Hepa1.6 cells expressing M, I, IC39S or IC232S were pulsed with 35S Met/Cys for
10 min and chased for the indicated times. AAT was immunoprecipitated from
the culture media and the intracellular fractions and analysed by non-reducing
8% SDS-PAGE and autoradiography. The kinetics of secretion of the mutants,
determined by densitometric analysis as in Supplementary Material, Figure S3,
is represented in the graphs as means and SD of two independent experiments.
Statistical significance of IC39S versus I secretion was determined at each chase
time point by t-test analysis: *P < 0.05; **P < 0.01.
646 | Human Molecular Genetics, 2016, Vol. 25, No. 4
 at U
niversitÃ









Figure 5. Preventing aberrant disulphide bond formation increases secretion of Z AAT. (A) Hepa1.6 cells expressing Z or ZC232S were pulsedwith
35SMet/Cys for 10 min and
chased for the indicated times. AAT was immunoprecipitated from the culture media and the intracellular fractions, and analysed by non-reducing 8% SDS-PAGE and
autoradiography. The kinetics of secretion of the AAT mutants, determined by densitometric analysis, is represented in the graph as means and SD of four
independent experiments. Statistical significance of ZC232S versus Z secretion levels was determined at each chase time point by t-test analysis: *P < 0.05; **P < 0.01;
***P < 0.001. (B) The kinetics of secretion of Z and ZC232S in three independent pulse-chase experiments performed in the absence or presence of 0.5 mM DTT are
represented in the graphs as means and SD. Statistical significance of DTT effect on secretion levels was determined at each chase time point by t-test analysis:
*P < 0.05; **P < 0.01; ***P < 0.001. Autoradiographies of one of the experiments quantified are shown in the left panels. (C) Hepa1.6 cells expressing M, I, Z or ZC232S were
incubated for 6 h in serum-free culture medium in the absence (NT) or presence of 2-ME or DTT at the indicated mM concentrations. AAT levels in the cell media were
quantified by sandwich ELISA using a standard curve of purified AAT and expressed for each variant as fold increase relative to NT sample, set as 1. Results from two
independent experiments, each one in duplicates, are presented as means and SD. Statistical significance was determined by one-way ANOVA followed by
Bonferroni’s post-hoc test using GraphPad Prism version 5 (GraphPad software Inc, San Diego, CA, USA): *P < 0.05; ***P < 0.001.
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mutants. These interactions may be favoured by cellular oxida-
tive conditions such as those observed in liver tissues of PiZ
mice (29). Under our experimental conditions, we did not detect
major disulphide interactions of AAT mutants with resident ER
isomerases. However this does not preclude their existence,
since such interactions are highly dynamic andmay form transi-
ently during protein folding. In our view such interactions with
isomerases and other ER protein folding quality-control proteins
are likely to occur. These could be further interrogated in future
high sensitivity (e.g. mass spectrometry-based) interactome
studies involving immunoprecipitation of intracellular aggre-
gates of AAT variants characterized here. Proteins identified as
potential interactors could then be validated by reciprocal immu-
noprecipitation and functional studies.
The Cys232-mediated dimers we observe for the Z and other
polymerogenic variants are reminiscent of those previously
reported for the truncated AAT variant NHK (334stop), whose
degradation requires EDEM (ER-degradation enhancing alpha-
mannosidase-like protein) and ERdJ5 (30,31). Moreover, the
intracellular accumulation of such dimers as NP40-insoluble ag-
gregates is consistentwith their incorporation intohighmolecular
weight polymers. However, disulphide-linkeddimerswere not im-
munoprecipitated effectively by the anti-polymermAb 2C1 raising
the possibility that in vivo these disulphide-linked states are incor-
porated in non-classical polymers that may co-exist alongside
polymers recognized by the 2C1 mAb. It is now known that AAT
and other members of the serpin protein superfamily to which it
belongs can assemble into a range of distinct polymeric conforma-
tions (1,32). The different polymer architectures sharemany char-
acteristics, but vary in the degree towhich each protein subunit is
folded relative to the native state. This could account for the differ-
ential recognition of AAT polymers by the 2C1 mAb described
here, with differently linked polymers having different predispos-
ition to abnormal disulphide bond formation. Alternatively, the
polymers may all be similar in structure but the observed disul-
phide bonding may cause disruption of the 2C1 epitope or render
it less accessible due to local effects.
Aberrant disulphide bonding by gain- or loss-of-cysteine mu-
tants expressed in the ER has been previously reported for other
genetic diseases (33–36). Cysteine-mediated retention of the I
AAT mutant is a striking example of the consequences of a
non-native cysteine in the protein maturation in the ER. The
presence of an additional cysteine residue (Cys39) in the Imutant
leads to the formation of an intra-chain andmultiple inter-chain
disulphide-linkages involving both Cys39 and Cys232. Gain-of-
cysteine AAT mutants may therefore be regarded as a subset of
AAT deficiency variants, with a distinctive molecular pathogen-
esis characterized by increased aberrant disulphide binding
events. Notably, our studies have also provided the first proof of
co-aggregation of different AAT deficiency variants in the ER.
Specifically, we observed formation of mixed disulphide com-
plexes by the co-expressed I andZmutants. Suchheteropolymer-
ization was previously hypothesized on the basis of biophysical
data in a cell-free model (9). Since polymer load correlates with
disease severity, this has implications for risk stratification of
compound heterozygotes such as the IZ cases reported in the
literature.
Our mutagenesis data formally demonstrate that aberrant
disulphide bonding can contribute to the secretory deficiency of
AATmutants in cells. This effect is particularly evident for I AAT.
Here aberrant and complex patterns of intra- and inter-molecu-
lar thiol interactions mediated by the two cysteines combine
with the inherent polymerogenic tendency of cysteine or
serine mutations at position 39. This combination enhances
intracellular aggregation of I AAT in away thatmakes in relatively
refractory to treatment with reducing agents at concentrations
previously used to modulate the ER folding and ER-associated
degradation (30,37,38). On the other hand, a simpler pattern of
aberrant disulphide bonding contributes to accumulation of the
most clinically important variant, Z AAT, within cells. This is
more tractable to anti-oxidant treatments to improve secretion.
Our data are consistent with the previous understanding that
non-covalent polymerization is the primarymechanism of intra-
cellular AAT retention, with abnormal disulphide bond forma-
tion playing an exacerbating role. Anti-oxidant strategies would
therefore be highly complementary to other approaches in
development to block or reverse polymerization (39).
Concluding remarks
Previous studies have established that misfolding and aberrant
conformational behaviour of AATmutants determine their intra-
cellular retention, degradation and tendency to form ordered
polymers. Here we show that cysteine-mediated interactions
within the ER contribute to the intracellular retention of the
AAT deficiency mutants. The ER redox state may therefore be re-




Unless stated otherwise, reagents and culture media were from
Sigma-Aldrich. The rabbit polyclonal anti-AAT was from DAKO;
the 2C1mAb (16)was kindly provided byDavid Lomas (CIMR,Uni-
versity of Cambridge, UK). The rabbit polyclonal anti-HA (H6908)
was from Sigma-Aldrich.
Expression vectors for the AAT variants
The Brixia allele was identified in amale heterozygous subject by
sequencing all coding exons (II–V) of the SERPINA1 gene (RefSeq:
NG_008290), as previously described (14). The expression vectors
encoding for human M1(Val213) and Z AAT were reported previ-
ously (14). The vectors for the tagged AAT variants M-myc, M-HA
and Z-HA (40) were kind gifts of Dr Giulia Baldini (University of
Arkansas for Medical Sciences, Little Rock, AR, USA). The vectors
encoding the Brixia, I and F variants, and the artificial mutants
IC39S, IC232S, ZC232S, I-myc and I-HA, were obtained by site-directed
mutagenesis, using the QuikChange II Site-DirectedMutagenesis
Kit (Stratagene) and the primers listed in Supplementary Mater-
ial, Table S1.
Cell culture and transfections
Hepa1.6 is a mouse hepatoma cell line (ATCC CRL-1830) grown in
dulbecco’s modified eagle medium (DMEM) supplemented with
10% fetal bovine serum. Transient transfections were performed
with Polyethyleneimine ‘MAX’ (PEI) (Polysciences). For a 10 cm2
well, 20 µg PEI and 3 µg plasmid were incubated for 20 min in
400 µl DMEM, diluted to 1.5 ml with normal culture medium
and added to the cell layer for 5 h.
Metabolic labelling experiments
Transiently transfectedHepa1.6 cellswere pulsed for 10 minwith
35SCys/Met (EasyTag™ Express Protein Labelling, Perkin Elmer) in
DMEM without Cys/Met-1% dialysed FCS, and then chased in
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normal culture medium for 0, 15, 30, 60, 120 and 240 min. Long
metabolic labelling was performed with 35S Cys/Met for 5 h.
After labelling, the media were centrifuged at 600g for 5 min
and supplemented with 10 mM NEM. Cells were washed with
phosphate buffered saline (PBS)/10 mMNEMand lysed in a buffer
containing 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP40,
10 mM NEM and protease inhibitors. The NP40-insoluble frac-
tions were separated by centrifugation at 12 000 g, dissolved in
a buffer containing 10 mM Tris, pH 7.4, 150 mM NaCl, 0.2%
NP40, 0.1% SDS, 1 mMMgCl2 and 20 µg/ml DNAse I, and finally di-
luted 10-fold with 1% NP40 buffer. The radiolabelled AAT in the
cell lysates and media was immunoprecipitated with an anti-
AAT polyclonal antibody (DAKO) and analysed by 8% SDS-PAGE
under reducing or non-reducing conditions followed by autoradi-
ography. Densitometric analysis of AAT bands was performed by
Image Quant 5.2 (Molecular Dynamics).
Diagonal gels
TheNP40-soluble cell extracts frommetabolically labelledHepa1.6
cells were resolved by SDS-PAGE in non-reducing conditions. All
the lanes were cut and reduced by incubation with 2× Laemmli
Sample Buffer containing 100 mM DTT for 10 min. For the second
dimension, lane slices were placed onto a 8% acrylamide gel and
run as a conventional SDS-PAGE followed by autoradiography of
the dried gels.
Western blot analysis
For immunoblot analysis, NP40-soluble cell extracts were ob-
tained from transfected Hepa1.6 cells as described above for
pulse experiments, resolved by SDS-PAGE on pre-casted 7.5%
mini PROTEAN TGX gels (Biorad) and transferred to LF-PVDF
membranes by the Turbo Blot Transfer System (Biorad). Mem-
branes were saturated in low-fat milk, probed with the indicated
primary antibodies and horseradish peroxidase (HRP)-conju-
gated secondary antibodies (GE Healthcare), revealed by ECL
(LiteAblot® plus, Euroclone).
Secretion assays and sandwich ELISA
To quantify secreted AAT, Hepa1.6 transfected cells werewashed
to remove serum and incubated for 6 h in serum-free cultureme-
dium, supplemented with 2-mercaptoethanol (2-ME) or DTT
when indicated. ELISA plates (half-volume, Costar) were coated
overnight at 4°C with 1 µg/ml anti-AAT antibodies (DAKO),
washed with PBS/0.1% Tween 20 (PBS-T) and then blocked with
0.25% BSA/PBS-T for 75 min at 37°C. Serial dilutions of cell
media were added to the plate and incubated at 37°C for 1 h.
For the standard curve, we used serial dilutions of purified AAT
(Millipore). Bound AAT was revealed by incubating for 1 h with
1 µg/ml HRP-conjugated goat anti-hAAT (Abcam) followed by
TMB-plus substrate (Thermo Scientific). After blocking the reac-
tion with 3 M HCl, absorbance was measured at 450 nm using
an ELISA plate reader.
Supplementary Material
Supplementary Material is available at HMG online.
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